BioSpace News Archive

MiMedx Group, Inc. today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP-120 (Ifenprodil) for IPF with cough as its key indication.

Microbot Medical Inc. (Nasdaq: MBOT), continuing its recent success of strengthening its Scientific Advisory Board with the recent recruitment of Key Opinion Leaders (KOLs), today announced that Ripal T. Gandhi, MD, FSVM, will join the Company’s robust Scientific Advisory Board (SAB).

Allakos Inc. today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share.

XORTX Therapeutics Inc. is pleased to announce completion of the previously announced Type B Pre-phase 3 meeting with the US Food and Drug Administration (“FDA”) held on September 16, 2022.

Psyence Group Inc. is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent regulatory body to Canada’s Health Canada and the US’s FDA.

HistoSonics announced today the publication of results from their prospective Phase I clinical trial, named the THERESA Trial, conducted in Barcelona, Spain.

Aclarion, Inc. announced today their participation in the Biomarkers for Evaluating Spine Treatments (BEST) Trial funded through the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM.

Trevi Therapeutics, Inc. today announced positive results from the full set of subjects in its Phase 2 Cough And NALbuphine (CANAL) trial of Haduvio for the treatment of chronic cough in IPF.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, and Providence, a not-for-profit health system serving the Western U.S., today announced a multi-system, national contract to acquire AquaBeam Robotic Systems.